Accugen Pty Ltd is a wholly-owned subsidiary of the Australian drug discovery company, Vectus Biosystems Limited. Accugen was found by the internal researchers as they had discovered a technique via absolute quantification in quantitative real-time polymerase chain reaction (qPCR) experiments. The method negates the need for housekeeping genes, requires no optimisation and is compatible with current instruments and techniques.
Accugen’s product consists of a consumable calibrator, called AccuCal-D™ (for use in dye-based assays) or AccuCal-P™ (for use in probe-based experiments – currently under development), and a software program called RealCount™. Together, they allow accurate, absolute quantification of qPCR product for each and every gene of interest, and make identification and validation of reference genes unnecessary.
Quantitative real-time polymerase chain reaction (qPCR) is a fundamental molecular biology technique, used in pharmaceutical research, biotechnology, molecular diagnostics, food safety, and academic research. Applications include gene expression analysis, identification of genetically modified organisms, diagnosis of bacterial and viral infections, and basic research.
Current methods for quantification of product in qPCR can be divided into two broad categories: absolute quantification and relative quantification. Absolute quantification involves the construction of a standard curve, using a serial dilution of a purified known starting copy number of the gene of interest. Relative concentration involves normalisation of the gene of interest to the level of one or more reference (or housekeeping) genes. Despite being a relatively mature technique, there remain a number of widely recognised issues with current techniques for quantification of product in qPCR experiments.
Using AccuCal™ calibrators and RealCount™ solves all of these issues.